These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 12879985)

  • 1. Bile duct disorders.
    Geubel AP; Sempoux C; Rahier J
    Clin Liver Dis; 2003 May; 7(2):295-309. PubMed ID: 12879985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-induced vanishing bile duct syndrome: response to ursodiol.
    O'Brien CB; Shields DS; Saul SH; Reddy KR
    Am J Gastroenterol; 1996 Jul; 91(7):1456-7. PubMed ID: 8678017
    [No Abstract]   [Full Text] [Related]  

  • 3. Ursodeoxycholic acid treatment of vanishing bile duct syndromes.
    Pusl T; Beuers U
    World J Gastroenterol; 2006 Jun; 12(22):3487-95. PubMed ID: 16773706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-associated acute-onset vanishing bile duct and Stevens-Johnson syndromes in a child.
    Srivastava M; Perez-Atayde A; Jonas MM
    Gastroenterology; 1998 Sep; 115(3):743-6. PubMed ID: 9721172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vanishing bile duct syndrome related to DILI and Hodgkin lymphoma overlap: A rare and severe case.
    Greca RD; Cunha-Silva M; Costa LBE; Costa JGF; Mazo DFC; Sevá-Pereira T; Nascimento MMC; Pereira IE; Oliveira FC; Faria GAS; Neto FLP; Almeida JRS
    Ann Hepatol; 2020; 19(1):107-112. PubMed ID: 31537508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-induced bile duct injury.
    Visentin M; Lenggenhager D; Gai Z; Kullak-Ublick GA
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1498-1506. PubMed ID: 28882625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Favourable long term effect of ursodeoxycholic acid treatment on congenital vanishing bile duct syndromes.
    Karageorgos SA; Tzardi M; Stratakou S; Voumvouraki A; Notas G; Kouroumalis E
    Acta Gastroenterol Belg; 2018; 81(2):330-332. PubMed ID: 30024707
    [No Abstract]   [Full Text] [Related]  

  • 8. Application of ursodeoxycholic acid (UDCA) in the therapy of liver and biliary duct diseases in children.
    Lebensztejn DM
    Med Sci Monit; 2000; 6(3):632-6. PubMed ID: 11208384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-induced cholestasis.
    Levy C; Lindor KD
    Clin Liver Dis; 2003 May; 7(2):311-30. PubMed ID: 12879986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vanishing bile duct syndrome: amoxicillin-clavulanic acid associated intra-hepatic cholestasis responsive to ursodeoxycholic acid.
    Smith LA; Ignacio JR; Winesett MP; Kaiser GC; Lacson AG; Gilbert-Barness E; González-Peralta RP; Wilsey MJ
    J Pediatr Gastroenterol Nutr; 2005 Oct; 41(4):469-73. PubMed ID: 16205517
    [No Abstract]   [Full Text] [Related]  

  • 11. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.
    Stiehl A; Rudolph G; Sauer P; Theilmann L
    J Hepatol; 1995 Sep; 23(3):283-9. PubMed ID: 8550992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic cholestatic diseases.
    Poupon R; Chazouillères O; Poupon RE
    J Hepatol; 2000; 32(1 Suppl):129-40. PubMed ID: 10728800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug and toxin-induced bile duct disorders.
    Geubel AP; Sempoux CL
    J Gastroenterol Hepatol; 2000 Nov; 15(11):1232-8. PubMed ID: 11129214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute vanishing bile duct syndrome after ibuprofen therapy in a child.
    Taghian M; Tran TA; Bresson-Hadni S; Menget A; Felix S; Jacquemin E
    J Pediatr; 2004 Aug; 145(2):273-6. PubMed ID: 15289784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vanishing bile duct syndrome associated with azithromycin in a 62-year-old man.
    Juricic D; Hrstic I; Radic D; Skegro M; Coric M; Vucelic B; Francetic I
    Basic Clin Pharmacol Toxicol; 2010 Jan; 106(1):62-5. PubMed ID: 19906050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A case of allopurinol-induced granulomatous hepatitis with ductopenia and cholestasis].
    Yoon JY; Min SY; Park JY; Hong SG; Park SJ; Paik SY; Park YM
    Korean J Hepatol; 2008 Mar; 14(1):97-101. PubMed ID: 18367862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meropenem-induced vanishing bile duct syndrome.
    Schumaker AL; Okulicz JF
    Pharmacotherapy; 2010 Sep; 30(9):953. PubMed ID: 20812433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study.
    Stiehl A; Rudolph G; Sauer P; Benz C; Stremmel W; Walker S; Theilmann L
    J Hepatol; 1997 Mar; 26(3):560-6. PubMed ID: 9075663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cholestasis: drug therapy].
    Leuschner U
    Praxis (Bern 1994); 1998 Nov; 87(46):1532-6. PubMed ID: 9857764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinicopathologic features of drug-induced vanishing bile duct syndrome].
    Ye LH; Wang CK; Zhang HC; Liu ZQ; Zheng HW
    Zhonghua Gan Zang Bing Za Zhi; 2017 Apr; 25(4):317-320. PubMed ID: 28494557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.